West Physicians Advocate for Oncology Patients at Capitol Hill

Posted by & filed under Uncategorized.

West Cancer Center & Research Institute proudly announces that two of their oncology providers, Dr. Michael Berry, Breast Oncology Surgeon and Dr. Gregory Vidal, Medical Oncologist and Director of Clinical Research recently visited Capitol Hill in Washington, DC.  They engaged with lawmakers from across the state and political spectrum to address crucial issues affecting cancer… Read more »

Updates in GI Cancers with Dr. Axel Grothey

Posted by & filed under Uncategorized.

Exciting updates in GI Cancers! Dr. Axel Grothey from West Cancer Center shared groundbreaking insights at the Total Health Spring Oncology Review and Renew Conference. He highlighted major advancements in targeted therapies and precision medicine for GI cancers. Here are the key highlights: Gastro-Esophageal Junction (GEJ) Cancers: Dr. Grothey revealed a new biomarker, Claudin 18.2… Read more »

West Seeks Patients with Breast Cancer Undergoing Lumpectomy Surgery for Clinical Trial Using Investigational Imaging Technology with Artificial Intelligence (AI)

Posted by & filed under Uncategorized.

Study Will Assess Impact on Positive Margin Rates West Cancer Center is seeking patients with breast cancer who are undergoing breast-conserving surgery, or a “lumpectomy,” for potential participation in a clinical trial. Dr. Richard Fine, Dr. Michael Berry, and Dr. Richard Gilmore are the breast surgeons participating in this trial. Breast Surgeon, Dr. Richard Fine,… Read more »

West is First in the Region to Offer FDA-Approved PSMA PET/CT Imaging for Prostate Cancer Across All Stages

Posted by & filed under Uncategorized.

West Cancer Center & Research Institute, a pioneer in radiology technology, now has a recently FDA-approved radiopharmaceutical agent: prostate-specific membrane antigen (PSMA).  This agent will be imaged with our state-of-art PET/CT imaging for men diagnosed with prostate cancer.   According to the American Cancer Society, 1 in 8 men will be diagnosed with prostate cancer… Read more »

Reversing resistance to PD-1 inhibitors with combination immunotherapy in patients with advanced melanoma

Posted by & filed under Uncategorized.

West Cancer Center & Research Institute’s Ari Vanderwalde, MD, MPH is a SWOG (a National Cancer Institute supported organization that conducts clinical trials in adults) investigator and study chair for a trial that addresses advanced melanoma patients who are resistant to PD-1 inhibitors. Over 40% of these patients don’t respond to PD-1 inhibitors, widely used… Read more »

2022 West Oncology Conference

Posted by & filed under Uncategorized.

We are so excited to announce West Cancer Center’s 7th Annual West Oncology Conference on February 25-26, 2022.  A distinguished panel of speakers from both West and cancer centers across the country, will present and discuss new research findings in oncology education. Participants will be provided with updates on practice-changing data in women’s cancers, genitourinary cancers, hematological… Read more »

Dr. Noam VanderWalde Publishes Study on Disparities in Older Adults

Posted by & filed under Uncategorized.

Dr. Noam VanderWalde, one of our incredible Radiation Oncologists here at West, is extremely passionate about geriatric oncology care. Below is a link to his most recent cooperative group publication, entitled “Disparities in older adult accrual to cancer trials: Analysis from the alliance for clinical trials in oncology (A151736).” Click the link below to read… Read more »

WEST FIGHT ON

Posted by & filed under Uncategorized.

​West Fight On returns to Shelby Farms Park on September 11, 2021   Get ready to cycle, run, or walk to beat cancer! West Fight On benefiting West Cancer Foundation will be LIVE and IN-PERSON this September!   This signature fundraising event will return to its home at Shelby Farms Park on Saturday, September 11,… Read more »

Dr. Daniel Vaena Co-Presented Data from Phase I Study at ASCO 2021

Posted by & filed under Uncategorized.

Dr. Daniel Vaena, Director of Experimental Therapeutics Program at West Cancer Center Research Institute, co-presented updated data from Compugen Ltd.’s Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo® (nivolumab)   Vaena states “Although these results are very preliminary, they suggest that targeting… Read more »